Characterization of Clonal B Cell Populations in HCV Infection
Completed
Conditions studied: Hepatitis C
In brief
The purpose of this study is to investigate the mechanism of autoantibody production during chronic hepatitis C virus (HCV) infection. 10-50% of individuals with HCV have symptoms of mixed cryoglobulinemia (MC). By studying the B cells from HCV-infected individuals with and without MC, as well as from healthy controls, we hope to gain insight into the mechanisms of autoantibody production and develop new strategies for treatment of MC.
Key facts
- Study ID
- NCT00435201
- Run by
- Rockefeller University
- People needed
- 14
- Starts
- 2007-01-01
- Expected to finish
- 2013-06-01
- Last updated by the study team
- 2013-08-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- At least 18 years of age.
- Ability to give informed consent.
- WBC greater than 3,000/mm3.
- Platelets greater than 80,000/mm3.
- Hb at least 9.5 g/dl.
- INR less than 1.5.
- Biologic therapy: Greater than 6 months post-Rituximab therapy.
- Greater than 6 months post IFN- alpha and Ribavirin therapy.
You may not qualify if…
- Decompensated cirrhosis.
- Serious uncontrolled medical illness.
- Receipt of immune modulators or suppressors within 30 days prior to study entry, including, but not limited to, interferons and thalidomide.
- Psychiatric illness or social condition that, in the opinion of the investigator, would interfere with adherence to study requirements.
- Alcohol or drug use or dependence that, in the opinion of the investigator,would interfere with adherence to study requirements.
Where it is running
- Rockefeller University Hospital — New York, New York, United States
- Oxford University — Oxford, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.